Our top pick for
Omnicell, Inc is a health information services business based in the US. Omnicell shares (OMCL) are listed on the NASDAQ and all prices are listed in US Dollars. Omnicell employs 2,780 staff and has a trailing 12-month revenue of around USD$906.4 million.
Since the stock market crash in March caused by coronavirus, Omnicell's share price has had significant positive movement.
Its last market close was USD$100.14, which is 11.99% up on its pre-crash value of USD$88.13 and 84.62% up on the lowest point reached during the March crash when the shares fell as low as USD$54.24.
If you had bought USD$1,000 worth of Omnicell shares at the start of February 2020, those shares would have been worth USD$710.39 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,217.70.
|Latest market close||USD$100.14|
|52-week range||USD$54.24 - USD$94.85|
|50-day moving average||USD$74.3985|
|200-day moving average||USD$69.7863|
|Wall St. target price||USD$79.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.133|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-16)||100.14|
|1 month (2020-10-26)||19.07%|
|3 months (2020-08-24)||47.22%|
|6 months (2020-05-22)||52.56%|
|1 year (2019-11-22)||26.50%|
|2 years (2018-11-23)||38.60%|
|3 years (2017-11-24)||99.88%|
|5 years (2015-11-24)||242.59%|
Valuing Omnicell stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Omnicell's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Omnicell's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 73x. In other words, Omnicell shares trade at around 73x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Omnicell's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.28. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Omnicell's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Omnicell's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$100.9 million.
The EBITDA is a measure of a Omnicell's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$906.4 million|
|Operating margin TTM||6.84%|
|Gross profit TTM||USD$436.9 million|
|Return on assets TTM||3.2%|
|Return on equity TTM||5.91%|
|Market capitalisation||USD$3.5 billion|
TTM: trailing 12 months
There are currently 2.8 million Omnicell shares held short by investors – that's known as Omnicell's "short interest". This figure is 22.6% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting Omnicell shares can be evaluated.
Omnicell's "short interest ratio" (SIR) is the quantity of Omnicell shares currently shorted divided by the average quantity of Omnicell shares traded daily (recently around 493100.89285714). Omnicell's SIR currently stands at 5.6. In other words for every 100,000 Omnicell shares traded daily on the market, roughly 5600 shares are currently held short.
However Omnicell's short interest can also be evaluated against the total number of Omnicell shares, or, against the total number of tradable Omnicell shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Omnicell's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Omnicell shares in existence, roughly 60 shares are currently held short) or 0.0892% of the tradable shares (for every 100,000 tradable Omnicell shares, roughly 89 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Omnicell.
Find out more about how you can short Omnicell stock.
We're not expecting Omnicell to pay a dividend over the next 12 months.
Over the last 12 months, Omnicell's shares have ranged in value from as little as $54.24 up to $94.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omnicell's is 0.8296. This would suggest that Omnicell's shares are less volatile than average (for this exchange).
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. In addition, the company provides single dose automation solutions to fill and label for incoming prescriptions; medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. Further, it offers Omnicell Patient Engagement, a web-based nexus of solutions; and patient communication tools, such as interactive voice response, outbound communications, and mobile app. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.